Literature DB >> 10594793

Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II.

J A Miller1, K Thai, J W Scholey.   

Abstract

UNLABELLED: Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II.
BACKGROUND: Most of the known actions of angiotensin II (Ang II) are mediated by the Ang II type 1 receptor (AGT1R). A noncoding polymorphism of the AGT1R gene has been described in which there is either an adenine (A) or cytosine (C) base at position 1166. The functional significance of this polymorphism is unknown, prompting us to examine the relationship between this polymorphism and the systemic and renal responses to AGT1R blockade and subpressor Ang II infusion.
METHODS: Sixty-six healthy Caucasian men and women, genotyped for the AGT1R polymorphism by polymerase chain reaction, were chosen to form two homogeneous groups: AA and AC/CC. Renal hemodynamic function was assessed with inulin and para-aminohippurate clearance before and after AGT1R receptor blockade with losartan and Ang II infusion.
RESULTS: The mean values at baseline for glomerular filtration rate (GFR), renal plasma flow (ERPF), and renal blood flow (RBF) were significantly lower in the AC/CC group compared with the AA group. Losartan increased the GFR and decreased the mean arterial pressure (MAP) in the AC/CC group, but did not influence these parameters in the AA group. The aldosterone responses to losartan were blunted in the AA subgroup. During Ang II infusion, AC/CC subjects maintained GFR despite equivalent declines in RBF, suggesting an enhanced efferent arteriolar constrictive response.
CONCLUSIONS: Taken together, these results suggest that there is a relationship between the AGT1R A1166-->C polymorphism and the humoral and renal hemodynamic responses to AGT1R blockade and to Ang II infusion in the sodium-replete state, and that the C allele is associated with enhanced intrarenal and peripheral Ang II activity. Further studies are required to determine the genetic locus for this effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594793     DOI: 10.1046/j.1523-1755.1999.00770.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

1.  Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Authors:  Takeshi Shiiki; Yukiya Hashimoto; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Luca Carta; Jason R Cook; Silvia Smaldone; Gabriella Siciliano; Aaron N Rifkin; Harry C Dietz; Daniel B Rifkin; Francesco Ramirez
Journal:  Hum Mol Genet       Date:  2010-09-24       Impact factor: 6.150

Review 3.  The ACE gene and human performance: 12 years on.

Authors:  Zudin Puthucheary; James R A Skipworth; Jai Rawal; Mike Loosemore; Ken Van Someren; Hugh E Montgomery
Journal:  Sports Med       Date:  2011-06-01       Impact factor: 11.136

4.  Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II.

Authors:  Hyeong-Seok Lim; Joo-Youn Cho; Dal-Seok Oh; Jae-Yong Chung; Kyoung-Sup Hong; Kyun-Seop Bae; Kyung-Sang Yu; Kyung-Hoon Lee; In-Jin Jang; Sang-Goo Shin
Journal:  Eur J Clin Pharmacol       Date:  2006-12-05       Impact factor: 2.953

Review 5.  Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

Authors:  Donna K Arnett; Steven A Claas
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

6.  Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis.

Authors:  Sharon M Moe; Jin Long; Tae-Hwi Linus Schwantes-An; Brian S Decker; Leah Wetherill; Howard J Edenberg; Xiaoling Xuei; Matteo Vatta; Tatiana M Foroud; Glenn M Chertow
Journal:  Nephrol Dial Transplant       Date:  2019-11-01       Impact factor: 5.992

Review 7.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

8.  Pharmacogenetics of cardiovascular drug therapy.

Authors:  Bas J M Peters; Olaf H Klungel; Anthonius de Boer; Bruno H Ch Stricker; Anke-Hilse Maitland-van der Zee
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 9.  Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?

Authors:  Donna K Arnett; Steven A Claas; Amy I Lynch
Journal:  Curr Opin Cardiol       Date:  2009-07       Impact factor: 2.161

10.  Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).

Authors:  Martin Brunner; Rhonda M Cooper-DeHoff; Yan Gong; Jason H Karnes; Taimour Y Langaee; Carl J Pepine; Julie A Johnson
Journal:  Am J Cardiol       Date:  2007-04-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.